Approach to hyperleukocytosis and leukostasis-inpatient management strategies.
Level V
Where this comes from
- Record sourced from PubMed, PMID 41058090.
- Also identified by DOI 10.1002/jhm.70199.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hyperleukocytosis is defined as a white blood cell count exceeding 100,000/µL and is a critical manifestation of acute and chronic leukemia. It can lead to life-threatening complications such as leukostasis, disseminated intravascular coagulation, and tumor lysis syndrome. Leukostasis results from microvascular obstruction by leukemic blasts, causing multisystemic manifestations. Leukostasis is primarily a clinical diagnosis requiring prompt recognition and intervention. Supportive care includes intravenous hydration, uric acid-lowering agents, and cautious blood transfusions to prevent worsening hyperviscosity. Hydroxyurea and cytarabine are used as cytoreductive agents until a definitive diagnosis and management are started. The role of leukapheresis is controversial, and practice patterns differ between clinicians and institutions.
Medical subject headings
- Leukostasis
- Leukocytosis
- Disease Management
- Leukemia
- Hospitalization